Dr. Pradhan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
900 Commonwealth Ave
Boston, MA 02215Phone+1 617-278-8777- Is this information wrong?
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2002 - 2005
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1996 - 1999
Georgetown University School of MedicineClass of 1996
Certifications & Licensure
MA State Medical License 1999 - 2024
Clinical Trials
- The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes Start of enrollment: 2006 Aug 01
- Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes Start of enrollment: 2010 Sep 01
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) Start of enrollment: 2017 Mar 23
Publications & Presentations
PubMed
- 8 citationsC-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations.Pascal M Burger, Aruna D Pradhan, Jannick A N Dorresteijn, Stefan Koudstaal, Martin Teraa, Gert J de Borst, Manon G van der Meer, Arend Mosterd, Paul M Ridker, Frank L...> ;The American Journal of Cardiology. 2023 Jun 15
- 6 citationsClinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3.Waqas A Malick, Ori Waksman, Ron Do, Wolfgang Koenig, Aruna D Pradhan, Erik S G Stroes, Robert S Rosenson> ;Journal of the American College of Cardiology. 2023 Apr 25
- 64 citationsInflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.Paul M Ridker, Deepak L Bhatt, Aruna D Pradhan, Robert J Glynn, Jean G MacFadyen, Steven E Nissen> ;Lancet. 2023 Apr 15
- Join now to see all
Journal Articles
- Trial Designs Rationale and Design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) Study☆Marshall Elam, Aruna D Pradhan, William R Hiatt, ScienceDirect
Press Mentions
Pemafibrate Reduces Triglycerides, but Not CV Events, in Patients with T2D, HypertriglyceridemiaDecember 23rd, 2022- Scientists Discover Surprising Effect Cholesterol-Lowering Drug Has on Heart Disease RiskNovember 14th, 2022
- PROMINENT: Pemafibrate Effective in Lowering Tryglycerides, but Not Reducing Risk of CV EventsNovember 5th, 2022
- Join now to see all
Grant Support
- Mechanisms Of Statin-Induced DM In Jupiter (Rosuvasatin For CVD Prevention)National Heart, Lung, And Blood Institute2010–2011
- Novel And Traditional Risk Factors For Symptomatic PAD In WomenNational Heart, Lung, And Blood Institute2007–2010
- Novel/Traditional Risk Factors--Symptomatic PAD In WomenNational Heart, Lung, And Blood Institute2006
Hospital Affiliations
Veterans Affairs Boston Healthcare SystemWest Roxbury, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
